Companies › Zhejiang Hisun Pharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AST-3424 AKR1C3 inhibitor | AKR1C3 | Phase 2 | HCC - Hepatocellular Carcinoma | Oct 2027 |
| HS387 | – | Phase 1 | Advanced Solid Cancers | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07310173 | AST-3424 | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Oct 2027 |
| NCT07092748 | HS387 | Phase 1 | Advanced Solid Cancers | Oncology | Jun 2028 |
–
Tianjin ConjuStar Biologics HitGen Shenzhen TargetRx Clarity Pharmaceuticals TYK Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.